9 employees
PolyProx Therapeutics is a developer of a novel class of drug intended to provide new therapies for cancer treatment.
2019
$4.4M
from 4 investors over 4 rounds
PolyProx Therapeutics Ltd raised $4.4M on April 30, 2019
Investors: Cambridge Innovation Capital plc, Cambridge Enterprise, Future Planet Capital and Parkwalk Advisors